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Abstract 
Purpose: To enhance the aqueous solubility and dissolution rate of elvitegravir (EVG) by formulating 
the drug as solid lipid nanoparticles (SLNs) using solvent injection method.  
Methods: EVG-loaded SLNs were prepared by solvent injection method. Four different formulations of 
SLN were prepared using gelucire - 44/14 as lipid core in ethanol, soya lecithin as emulsifier, and 
polysorbate 80 as surfactant in the aqueous phase. The SLNs were characterized for various physical 
properties, including particle size, zeta potential, polydispersity, release profile and entrapment 
efficiency. 
Results: The yield of SLNs was in the range 151.0 ± 2.4 to 199.1 ± 2.7 nm. Significant changes were 
observed in mean particle size (nm), Z - potential (mV) and polydispersity index (PDI) of the SLNs by 
varying the concentration of cryoprotectant. EVG – SLNs demonstrated a 800 – 1030-fold enhancement 
in aqueous solubility compared with plain EVG. The dissolution efficiency (DE) for SLNs was > 63 % in 
all cases and increased up to 83 % with increasing lipid load. 
Conclusion: Successful preparation and characterization of elvitegravir–loaded solid lipid nanoparticles 
by solvent injection method has been accomplished in this study.  
 
Keywords: Elvitegravir, Solid lipid nanoparticles, Cryoprotectant, Lipid load, Entrapment efficiency 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Solid lipid nanoparticles are colloidal carrier 
systems for controlled drug release. The main 
advantage of SLN’s over liposomes, polymeric 
nanoparticles and polyester nanoparticles is the 
lipid matrix which decreases the danger of acute 
and chronic toxicity and has good tolerability [1-
3]. The other important application of SLN’s is 
improved bioavailability by oral administration 
and increased targeting ability of the drug [4,5]. 
  
Various methods are available for the 
preparation SLN’S which include high pressure 
homogenization, high speed homogenization, 
micro emulsion based SLN preparation, double 
emulsion method, solvent emulsification/ 
evaporation, spray drying method, super critical 
fluid method and solvent injection method [1,6-8]. 
The present investigation uses solvent injection 
method to prepare EVG-loaded SLNs which is 
based on the injection of organic phase 
containing drug in to continuously stirred 
aqueous phase containing emulsifier and 
surfactant [9-11].  
 
Elvitegravir is a low molecular mass drug 
(447.883 g/mol) with the chemical name, 6-[(3-
Chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-
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3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-
carboxylic acid, and empirical formula, 
C23H23ClFNO5 [12,13]. The chemical structure of 




Figure 1: Chemical structure of Elvitegravir 
 
EVG belongs to a class of HIV drugs called 
integrase inhibitors which blocks HIV enzyme 
called integrase [14]. EVG is characterised with 
poor aqueous solubility so the main intend of the 
present study is to prepare EVG-loaded SLNs by 
solvent injection method with enhanced aqueous 




EVG was supplied by PharmaTrain (Hyderabad, 
India), Gelucire 44/14 was a gift sample from 
Gattefossé (France), Ethanol Absolute 99.9 % 
was from Commercial Alcohols (Brampton, 
Canada), Soya lecithin was from VWR 
International Ltd (Poole, England), polysorbate 
20 was from Merck Specialities Pvt Ltd (Worli, 
Mumbai), Ultra-pure water (Millipore®, USA) was 
used for the preparation of aqueous phase. D-
mannitol (≥ 98 %) here which is used as a cryo-
protectant was from Sigma-Aldrich (Saint Louis, 
USA). All the chemicals used were analytical 
reagent grade and used without further 
purification. 
 
Preparation of EVG-SLNs 
 
The EVG-loaded SLNs (EVG-SLNs) were 
prepared by solvent injection method followed 
ultra-sonic homogenization. In brief, 300 mg EVG 
and 150 mg Gelucire 44/14 were dissolved in 
ethanol which constitutes organic phase. The 
aqueous phase consists of 1 % w/v polysorbate 
20 as a surfactant and 1 % w/v soya lecithin as 
an emulsifier in water. The organic phase (5 ml) 
was injected rapidly through an injection needle 
in to continuously stirred aqueous phase (45 ml). 
The precipitate was stirred at 1500 rpm for 120 
min.  The resultant SLN suspension (EVG - 
SLN1) was homogenised in an Ultrasonic 
Homogenizer for 30 min. Similarly, three more 
SLN suspensions EVG - SLN2, EVG - SLN3 and 
EVG -SLN4 were prepared by varying lipid 
weight 300 mg, 450 mg and 600 mg respectively. 
EVG - SLNs were optimized for lipid 
concentration and the effect of variation of lipid 
ratio on particle size, zeta potential, 
polydispersity index, entrapment efficiency and 
drug release kinetics were evaluated. Effect of 
addition of cryo-protectant on particle size, zeta 
potential and PI were studied up on immersing 
EVG - SLN’s in to liquid nitrogen. 
 
Particle size analysis 
 
The mean particle size (Z - Average) analysis 
and polydispersity index (PDI) were determined 
by dynamic light scattering (DLS) principle 
(Zetasizer nano ZS, Malvern Instruments, UK) 
after appropriate dilutions in Milli Q water filtered 
through 0.22 µm polyvinylidene difluoride (PVDF) 
filters. Size measurement was carried out in 
triplicate following proper dilutions in Milli Q water 
at 25 oC using DTS0012 –clear disposable sizing 
cuvettes with equilibration time 120 s. The test 
was conducted at an angle of 173o backscatter 
(NBS default) with measurement position set at 
4.65 mm. 
 
Zeta potential analysis  
 
The electrophoretic mobility of nanoparticles was 
determined using Electrophoretic Light Scattering 
principle (zetasizer nano ZS, Malvern 
Instruments, UK). Measurements were carried 
out in triplicate at 25 oC using water as a 
dispersant (refractive index: 1.330) in a clear 
disposable zeta cell. 
 
Morphological characterization by SEM 
measurement 
 
The morphology of the nanoparticles was 
investigated by scanning electron microscopy 
(SEM, JOEL JSM-6380) at an accelerating 
voltage of 10 kV. Double coated carbon 
conductive tabs were mounted on SEM sample 
stubs and pasted round glass coverslips on it 
and the sample was transferred and spread 
uniformly on the coverslips and conductive 
carbon paint is applied along the edges of 
coverslips and the sample is allowed to air dry. 
The samples were coated by Platinum Sputter 
Coater vacuum coater (JEOL, JFC 1600, Auto 
fine Coater) to minimize electrostatic charging.  
 
Solubility measurement of EVG and EVG-
SLNs 
 
The equilibrium solubility of the pure drug EVG in 
water was determined by the traditional shake 
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flask method. According to this method the drug 
is added in surplus to 5 ml of water and shaken 
for 24 h at 37 oC until equilibrium is reached. The 
saturation is confirmed by observation of the 
presence of un-dissolved material. After 
separation of the solid by filtration, the 
concentration of the drug in the filtrate was 
determined by UV Vis Spectrophotometer 
(LABINDIA-UV 3000+) at 257 nm against known 
standard concentration preparation. For the 
estimation of soluble fraction of drug in EVG - 
SLN’s, 5 ml of the suspension is taken and 
filtered through 0.45 µm filters and determined 
the solubility of EVG in EVG - SLN’s against 
known standard at 257 nm. 
 
Determination of drug entrapment efficiency 
 
EVG-SLN’s were centrifuged at 15000 rpm at 5 
oC for 30 min using Thermo Scientific IEC CL31 
Multispeed centrifuge. Entrapment of EVG in 
EVG-SLN’s was determined as in Eq 1. 
 
Entrapment (%) = {(W1-W2)/W1}100 ............. (1) 
 
where W1 is the total amount of drug added 
during EVG-SLN’s preparations. W2 is the 
amount of drug present in the clear supernatant 
layer, determined by UV-Vis spectrophotometer 
at 257 nm. 
 
In vitro dissolution studies 
 
In vitro release of the drug and EVG SLN’s was 
studied in USP-II apparatus using 2 % 
polysorbate 80 in 0.01N Hydrochloric acid as 
dissolution medium. The medium was stirred at 
75 rpm at 37 oC ± 0.5 oC. EVG SLN’s suspension 
equivalent to 5 mg of EVG was transferred into 
dissolution medium. At predetermined time 
intervals (ranging from 10 to 60 min), 5 ml of the 
sample medium was taken and the same amount 
of fresh medium was replaced. The amount of 
EVG released was determined using its 
absorbance at 257 nm. Different mathematical 
models were applied to the dissolution data of 
EVG - SLN’s to study the drug release kinetics. 
The most common mathematical models used 
for the evaluation of dissolution profile are listed 
in Table 1. Where Qt amount (%) of drug 
substance released at the time t, Q0 is the start 
value of Qt, t is the time, n is the release 
exponent, a is the scale parameter, b is the 
shape parameter and K0, K1, K, KS and KH are 





Data were analysed by Microsoft Office 
Enterprise 2007, Version 12.0.6612.1000. 
Statistical assessment of dissolution data of EVG 
and EVG SLNs was done by ANOVA: single 
factor and t-test; paired two-sample for means, 




Solvent injection method was selected for the 
preparation of EVG loaded SLN’s which depends 
on the rapid diffusion of solvent across the 
solvent lipid interface with the aqueous phase 
[15]. EVG - SLN’s were optimized for process 
variables like stirring speed, stirring time, 
sonication time and the effect of variation in lipid 
concentration on particle size, PDI and EE. The 
mean particle size of EVG - SLN1, EVG - SLN2, 
EVG - SLN3 and EVG - SLN4 were found to be 
151.0, 174.8, 182.3 and 199.1 nm, respectively, 
with unimodal distribution and PDI value is < 0.5 




Table 1: Kinetic models for dissolution profile evaluation 
 
Kinetic model Mathematical equation 
Zero order kinetic model Qt = Q0 + K0t 
First order kinetic model ln Qt = ln Q0 + K1t 
Second order kinetic model 1/Qt = Kt + 1/ Q0 
Third order kinetic model 1/Qt2 = Kt + 1/Q02 
Korsmeyer-Peppas model Qt= k tn 
Weibull model Log[-ln(1- (Qt/ Q∞))] = b X log t – log a 
Hixson-Crowell model Qo1/3- Qt1/3 = KS t 
Higuchi model Qt = KH √t 
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Table 2: Mean particle size (nm), Z - potential (mV), polydispersity index (PDI) and entrapment efficiency (%) of 
EVG-SLN’s containing different percentages of Gelucire 44/14 (n = 3) 
 







EVG - SLN1 151.0 ± 2.4 -41.4 ± 1.6 0.314 ± 0.051 77.3 ± 1.56 
EVG - SLN2 174.8 ± 3.2 -38.9 ± 0.4 0.383 ± 0.032 80.8 ± 0.86 
EVG - SLN3 182.3 ± 1.8 -39.8 ± 0.7 0.408 ± 0.036 84.1 ± 1.81 
EVG - SLN4 199.1 ± 2.7 -37.4 ± 1.0 0.420 ± 0.029 89.7 ± 0.27 
 
As the amount of lipid concentration increased 
the particle size of EVG - SLN’s increased from 
151.0 nm to 199.1 nm. Table 2 also reports the Z 
- potential values of EVG - SLN indicating the 
formation of stable suspension. The entrapment 
efficiency (%) of EVG-SLN’s was greater than 75 
% for all the preparations and increased as the 
lipid load increase. 
 
Initially, when the stirring rate was for 30 min 
uneven aggregates were observed resulting in 
non-homogenous suspension. The irregular 
aggregates with higher particles and high PDI 
value is due to increased viscosity of organic 
phase because of increasing lipid concentration 
resulting in slower diffusion of organic phase in 
the outer phase. Further increasing the stirring 
time from 30 min to 120 min resulted in 
homogenous suspension with low particle size 
and low PDI values. When the ultra sonic 
homogenization increased from 15 min to 30 min 
resulted in uniform particles with less particle 
size diameter. On further increasing the 
homogenization time to 45 min, no significant 
change in particle size is observed.  
 
Lyophilization of particles was carried out using 
mannitol to limit the risk of aggregation of 
particles. EVG - SLN nanosuspension’s 
containing 2, 5, 10 and 15 % mannitol as 
cryoprotectant was snap-frozen in liquid nitrogen. 
EVG - SLN suspensions without the addition of 
cryoprotectant were immersed in liquid nitrogen 
and found that mean particle size for EVG - 
SLN1, EVG - SLN2, EVG - SLN3 and EVG - 
SLN4 were 124.8, 141.9, 139.3 and 165.1 nm 
respectively. It is found that the mean particle 
size is decreased when compared to initial 
values and found that the Z - potential values 
ranged from -17.2 to -5.5 mV indicating the 
decrease in stability of the EVG - SLN’s up on 
immersing in liquid nitrogen. Effect of addition of 
different concentrations of mannitol as 
cryoprotectant on mean particle size, Z - 
potential and PDI are studied and the results are 
tabulated in Table 3.  
 
From these results it is found that for all the EVG 
- SLN preparations as the cryoprotectant 
concentration increased mean particle size 
ranging between 155.4 nm to 648.9 nm. The Z - 
potential value for EVG - SLN1 and EVG-SLN2 
ranged from - 47.4 mV to - 32.1 mV indicating 
the stability up on snap freezing but for EVG - 
SLN3 and EVG - SLN4 the Z - potential value 
decreased significantly and the values ranged 
from - 29.5 mV to - 8.6 mV indicating the reduced 
stability which may be due to increased particle 
aggregation. The PDI value is less than 0.5 for 
EVG - SLN1 and EVG - SLN2 with narrow 
particle size distribution indicating polydisperse 
colloidal dispersion and greater than 0.5 for EVG 
- SLN3 and increased further for EVG - SLN4. 
 
Imaging of SLNs by SEM is expected to provide 
information on SLN morphology and size. SEM 
images of the SLNs derived EVG are presented 
in Figure 2. Micrographs of SEM confirm that the 
EVG - SLN’s are circular in shape. 
 
The solubility results show that the aqueous 
solubility of EVG is 0.0016 mg/ml which indicates 
the practically insoluble nature of the drug. After 
the formation of SLN’s the solubility of EVG - 
SLN1, EVG - SLN2, EVG - SLN3 and EVG - 
SLN4 increased to 1.29, 1.47, 1.57 and 1.65 
mg/ml, respectively, an increase in solubility 
ranging from 806 to 1031-fold, respectively. 
  
In vitro dissolution 
 
EVG exhibits slow dissolution rate, only about 16 
% of the drug was dissolved in first 15 min and 
about 40 % of the drug was dissolved after 60 
min. After SLN formation in all the cases drug 
release was more than 50 % and increased up to 
74 % as the lipid load increased. The drug 
release profiles from the EVG-SLN’s prepared by 
the solvent injection method in aqueous system 
exhibited a linear relationship for Weibull model 
after the burst of drug (Figure 3). 
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Table 3: Effect of various concentrations of cryoprotectant on mean particle size (nm), Z - potential (mV) and 











EVG-SLN1 2 % 155.4 ± 2.8 -44.7 ± 2.1 0.380 ± 0.016 
5 % 212.3 ± 3.3 -46.4 ± 0.9 0.321 ± 0.011 
10 % 345.9 ± 2.3 -41.3 ± 1.7 0.397 ± 0.014 
15 % 453.8 ± 1.8 -35.6 ± 2.2 0.388 ± 0.009 
EVG-SLN2 2 % 181.1 ± 2.5 -43.8 ± 3.2 0.435 ± 0.012 
5 % 314.6 ± 5.8 -45.2 ± 2.1 0.311 ± 0.012 
10 % 428.1 ± 4.4 -47.4 ± 4.3 0.287 ± 0.023 
15 % 583.3 ± 3.2 -32.1 ± 1.1 0.398 ± 0.013 
EVG-SLN3 2 % 190.6 ± 3.8 -29.5 ± 0.7 0.545 ± 0.019 
5 % 321.0 ± 5.2 -22.8 ± 1.8 0.593 ± 0.018 
10 % 500.2 ± 3.1 -24.9 ± 4.1 0.653 ± 0.011 
15 % 612.2 ± 2.7 -22.2 ± 3.3 0.698 ± 0.020 
EVG-SLN4 2 % 210.6 ± 1.9 -17.8 ± 4.2 0.726 ± 0.012 
5 % 398.4 ± 3.0 -13.3 ± 0.9 0.965 ± 0.020 
10 % 498.9 ± 2.2 -13.1 ± 3.8 1.075 ± 0.011 




Figure 2: SEM micrographs of SLN’s showing the shape of (a) EVG - SLN1, (b) EVG - SLN2, (c) EVG - SLN3 




Figure 3: Dissolution profile of EVG – SLN systems compared to EVG, Note: ∆ = EVG; ■ = EVG – SLN1; ▲= 
EVG – SLN2; □ = EVG – SLN3; ◊ = EVG – SLN4 
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Coefficient of determination (R2), scale 
parameter (a) and shape parameter (b) results 
for EVG-SLN’S are tabulated in Table 4. 
 
Table 4 also presents the values of Dissolution 
efficiency (DE) which is the area under the 
dissolution curve between time point’s t1 and t2 
expressed as a percentage of the curve at 
maximum dissolution, y100, over the same 
period and is expressed as in Eq 2. 
 
DE = {[ʃt1t2y.dt]/[y100(t2-t1)]} × 100 ……...…..(2) 
 
DE values are related with the real amount of 
drug dissolved in the dissolution medium and 
thus, lead to a better extrapolative for in vivo 
performance [22]. From the table 4 it is observed 
that DE increased as the lipid concentration 
increased. 
 
Statistical assessment of the dissolution data 
was performed using analysis of variance 
(ANOVA-single factor).  From ANOVA - single 
factor results of EVG- SLN’s dissolution data, F 
value of EVG - SLN1, EVG - SLN2, EVG - SLN3 
and EVG - SLN4 is found to be 9.6, 28.5, 19.3 
and 29.5 respectively. The F-value for all the 
SLN preparations was > Fcrit-value, i.e., 4.96. 
The p-values of EVG - SLN1, EVG - SLN2, EVG 
- SLN3 and EVG - SLN4 are found to be 0.0112, 
0.0003, 0.0013 and 0.0003 respectively which 
are significantly smaller than 0.05.  
 
Based on the extremely low p-values and F-
value > Fcrit-value it can be deduced that there 
is a significant difference between the groups i.e. 
each of the EVG - SLN preparation significantly 
different in terms of percent dissolved at each 
time point. Further statistical assessment of the 
EVG and EVG SLN’s dissolution data were 
performed using t-Test: Paired Two Sample for 
Means. The absolute t Stat values for EVG - 
SLN1, EVG - SLN2, EVG - SLN3 and EVG - 
SLN4 were found to be 10.826, 21.505, 32.436 
and 21.072 respectively which are greater than t 
Critical two - tail value 2.571. Hence, from these 
findings it was concluded that there is a 
difference in the drug release profiles of EVG 




The use of solvent injection method for the 
preparation of EVG loaded SLN’s found to be 
advantageous in obtaining SLN with small, 
monodisperse nanoparticles with high 
Entrapment efficiency. The measurement of Z - 
potential allows the prediction of the storage 
stability of colloidal dispersion [16]. The Z - 
potential values did not change notably by 
increasing the lipid load and the obtained Z - 
potential values indicate the formation of stable 
suspension and there is no particle aggregation 
observed which is due to charged particles with 
high Z - potential due to electric repulsion 
[17,18]. In the present study, stable EVG – SLNs 
was prepared with Z - potential values ranging 
between -41.4 ± 1.6 to -37.4 ± 1.0. When the 
cryoprotectants are added in different 
concentrations to improve the chemical and 
physical stability of SLN over an extended period 
of time during lyophilisation and from Z - potential 
values it was observed that EVG – SLN1and 
EVG – SLN2 were stable over entire 
concentration range but for EVG – SLN3 and 
EVG – SLN4 decline in the Z - potential values 
ranging from 29.5 ± 0.7 to -8.60 ± 3.6 has been 
observed which may be due to the damage of 
surfactant film around the nanoparticle due to a 
freezing out effect and may also because of 
particle aggregation during the redispersion 
process [19,20]. 
 
There was a tremendous increase in solubility 
and dissolution rate and this may be due to 
reduction in particle size resulting in increase in 
surface area and saturation solubility which is a 
key factor for improving the performance of 
poorly soluble drugs. In vitro release tests have 
confirmed that release velocity from SLNs is 
significantly faster and the release kinetics of the 
drug from EVG - SLN’s is best described by 
Weibull mathematical model. 
 
Table 4: Parameters of Weibull mathematical model and dissolution efficiency (DE) results for the dissolution 











efficiency (DE, %) 
EVG - SLN1 0.9805 0.95 0.95 63.6 
EVG - SLN2 0.9883 0.82 9.03 72.9 
EVG - SLN3 0.9972 0.82 7.16 78.8 
EVG - SLN4 0.9262 2.15 219.55 82.9 
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Weibull equation expresses accumulated fraction 
of drug (m), in solution at time at time (t) and is 
given by following expression: 
  
m = 1 – exp {[-(t-Ti)b]/a} …………………….. (3) 
 
In this equation (3), ‘a’ is the scale parameter 
which defines the time scale of the process. ‘b’ is 
the shape parameter which characterizes the 
curve as either sigmoid (b = 1), S - shaped with 
upward curvature followed by a turning point (b > 
1) or parabolic, with a higher initial slope and 
after that consistent with the exponential (b < 1). 
‘Ti’ is the location parameter which represents 
the lag time before the onset of the dissolution 
and in most cases it will be zero [21]. 
 
The use of SLNs opens up new perspectives for 
the formulation of poorly soluble drugs. The poor 
aqueous solubility of EVG also makes it difficult 
to prepare parenteral formulations which can be 




This study demonstrates that EVG loaded SLN’s 
were successfully prepared and characterized. 
Thus, solvent injection technique seems a 
suitable method for the preparation of 
nanosuspension of poorly water-soluble drugs, 
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